Profil新闻

我们的专家

Lars Bochmann 博士

市场与业务发展执行总监

三月 26, 2024

First drug approved for NASH

On March 14, 2024, Madrigal Pharmaceuticals received the first regulatory approval for a drug targeting NonAlcoholic SteatoHepatitis (NASH). Specifically, FDA approved Rezdiffra (resmetirom) for the

一月 9, 2024

BfArM speeds up the approval process for clinical trials in Germany

With the implementation of the Clinical Trials Regulation 536/2014 (CTR) and the Clinical Trials Information System (CTIS) on 31st of January 2022, the European Union has embarked on a transformative

十一月 23, 2023

Correct interpretation of key CGM metrics

Glucose measurements are crucial for good glycaemic control in persons with diabetes. Besides self-monitoring of blood glucose (SMBG) with a few glucose measurements per day, nowadays continuous

十月 13, 2023

GLP-1 based drugs: Could Elon Musk’s weight loss weapon help us, too?

GLP-1 (glucagon-like peptide-1) receptor agonists have gained significant popularity due to their potential for weight loss. While some celebrities, such a tech billionaire Elon Musk [1], have

九月 26, 2023

Profil's scientific publications in 2023 - an overview

This is a short overview of key features and results of clinical trials performed at Profil and papers with Profil authorship that were published between January and August 2023. The clinical trial

八月 9, 2023

A novel long-acting Amylin analogue for the management of obesity

Introduction The prevalence of overweight and obesity is increasing worldwide [1]. Being overweight or obese amplifies the risk of other related diseases which can severely impair quality of life [2,

七月 25, 2023

Free Live Online Seminar: IMP management services for multi and single-center clinical trials in EU

We are happy to announce that our successful series of scientific online seminars continues. On August 22nd, 2023 at 6 PM CEST we will air our next complimentary live online seminar. The session is

七月 12, 2023

CTR 536/2014: First approvals and our experience with CTIS (Part 3)

As previously reported, the Clinical Trial Information System (CTIS) can help to get a faster approval for a multi-national, multicentre Phase III Study (read here part 1 and part 2 of the REGULATION

六月 29, 2023

Profil World - The clinical diabetes research newsletter - Jun 2023

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. On-demand